NSCLC is the most common type of lung cancer, accounting for about 85% of cases, and progresses more slowly than other forms of lung cancer.
Non-Small Cell Lung Cancer
Hightower Clinical aimed to explore a drug’s potential role as a possible treatment option for advanced NSCLC and other solid tumors.
About Non-Small Cell Lung Cancer Study
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of cases. It generally progresses more slowly than small cell lung cancer, often develops in the outer regions of the lungs, and includes various subtypes.
Hightower Clinical conducted a study to evaluate the safety and effectiveness of a bispecific antibody in patients with advanced NSCLC and other solid tumors. The goal was to test the drug as monotherapy or in combination with treatments like Osimertinib or chemotherapy.
Current Status
Not Recruiting
Study Count
1
Study Information
Non-Small Cell Lung Cancer
| Study Name | Protocol Number | Sponsor |
|---|---|---|
| Non-Small Cell Lung Cancer | Merus N.V. |
Frequently Asked Questions
What are the risk factors for NSCLC?
Risk factors for NSCLC include smoking, exposure to secondhand smoke, air pollution, and harmful substances like asbestos or radon, as well as a family history of lung cancer.
What complications can arise from NSCLC?
Complications of NSCLC can include difficulty breathing, chest pain, fatigue, and, if the cancer spreads, issues in other organs like the liver, bones, or brain.
Why should I participate in a study on NSCLC?
Participating in a study can help contribute to medical research, improve treatment options, and provide access to potential new therapies for managing advanced NSCLC.
Unlock New Opportunities in Clinical Research - Join Today!
We're here and eager to assist. Reach out to Hightower Clinical Research in Oklahoma City, OK for further details on how we can support you.
Get Involved Today!
© Copyright 2024 – Hightower Clinical. CREATED BY DIGITAL AUXILIUS.